Amide Compounds Inhibiting Microglial IL-1β Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nerve inflammatory diseases, such as Alzheimer's, fail to effectively suppress microglial activation and subsequent IL-1β secretion, leading to ongoing nerve inflammation and tissue damage.
Innovation Solution
Development of a compound represented by formula (I) and its pharmaceutical salts, which selectively inhibit microglial activation pathways, thereby reducing IL-1β secretion and treating nerve inflammatory diseases by administering a treatment-effective dose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for nerve inflammatory diseases are used, then general anti-inflammatory effects are achieved, but microglial activation and IL-1β secretion are not effectively suppressed
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formula I) that target the IL-1β secretion pathway in microglia. The compound structure includes specific heterocyclic groups and substituent patterns that optimize binding affinity and selectivity for the inflammatory pathway, thereby changing the therapeutic parameter from general anti-inflammatory to specific microglial activation suppression.
Solution Approach 2:
The compound of formula (I) acts as an intermediary substance that mediates between the microglial activation pathway and the inflammatory response. It specifically interferes with the signaling cascade that leads to IL-1β secretion, blocking the harmful effect without completely shutting down microglial function, thus providing selective inhibition.
2Reliability
If microglial activation is suppressed to treat nerve inflammatory diseases, then IL-1β secretion is reduced, but selective inhibition of the activation pathway is needed to avoid side effects
Solution Approach 1:
The patent applies local quality by designing the compound to act specifically on the IL-1β secretion pathway in microglia rather than broadly suppressing all inflammatory responses. The molecular structure is optimized to bind selectively to targets involved in microglial activation, providing localized therapeutic action at the cellular and molecular level while sparing other physiological functions.
Solution Approach 2:
The compound structure is segmented into specific functional groups (heterocyclic groups at positions R1, R2, R3, R4, R5 and Ar) that collectively provide selective binding to the microglial activation pathway. Each substituent contributes to the overall selectivity and affinity, allowing the molecule to target specific receptors or signaling components involved in IL-1β secretion.
Data Source
AI summary
A compound represented by formula (I) and the pharmaceutical acceptable salt thereof are disclosed,wherein, R1, R2, R3, R4, R5 and Ar are defined as those in the specification.